Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2024 16:01 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
October 26, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s enLIGHTEN™ Discovery Platform Both parties retain rights in...
September 06, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Upcoming Investor Conference Participation

NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
August 05, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
August 01, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Appoints Three New Members to its Board of Directors

Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO and Chief Executive Officer, ModeX Therapeutics, Inc., an OPKO Health companyJoseph Papa, Chief Executive Officer of Bausch + Lomb...
May 26, 2022 17:30 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that was ongoing at data cutoff in 62.5 percent of...
May 18, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
May 12, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
April 27, 2022 16:00 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...